MolecuLight signs purchasing agreement with AllSpire

Canadian medical device company MolecuLight has secured a group purchasing agreement with the US-based AllSpire Health GPO for wound imaging devices.

Under the terms agreed, MolecuLight’s i:X and DX point-of-care wound imaging devices will be available to the members of AllSpire.

AllSpire aggregates the purchasing volumes and expenses and streamlines supplier negotiations across the supply chain to help health systems optimise their operations.

MolecuLight’s imaging devices are claimed to be the only devices of their kind to have received US Food and Drug Administration (FDA) approval.

They allow clinicians to visualise the presence, location and load of bacteria present in wounds in real-time.

Findings from a 14-site clinical trial involving 350 patients demonstrated that the clinical standard of care alone detected 15% of wounds, while the use of MolecuLight devices led to a 400% improvement in wound detection.

MolecuLight CEO Anil Amlani said: “We are thrilled to have entered into a supply contract with AllSpire Health GPO.

“Through the i:X and DX, we hope to enable significant cost-savings and improvements in clinical outcomes. Medical Device Network